Renal Solutions To Present At The CIBC World Markets Fifteenth Annual Healthcare Conference

WARRENDALE, Pa., Nov. 5 /PRNewswire/ -- Renal Solutions, Inc. announced today that it will present at the CIBC World Markets Fifteenth Annual Healthcare Conference on Tuesday, November 9, 2004 at 3:00 p.m. Eastern Time at The Plaza Hotel in New York City.

Peter M. DeComo, Chairman and CEO of Renal Solutions, Inc., will present an overview of the Company and its progress in the commercialization of its revolutionary technology, The Allient(R) Sorbent Hemodialysis System. The presentation will be webcast live over the Internet. To listen to this presentation, log onto http://www.renalsolutionsinc.com/ and go into the webcast link on the home page or the following link http://veracast.com/webcasts/cibcwm/healthcare04/72213494.aspx .

Renal Solutions, Inc., a medical device and health-care service company, is developing a revolutionary technology/service solution for the home and acute dialysis market and has a distinct competitive advantage as the only provider of dialysis products and services utilizing sorbent-based toxin removal technology. Using the unique, pressure controlled Pulsar Blood Movement System(TM) and sorbent dialysate regeneration, hemodialysis can be delivered in the home or clinical environment. The Allient(R) System requires only 6 liters of tap water. This capability eliminates the need for complex technology to create a purified water source as with conventional dialysis technology. The Allient(R) is transportable and can be used anywhere standard power and drinking water can be accessed. Renal Solutions is a privately held company focused on providing revolutionary products and service that improve quality of life and aide in the reduction of the total cost of treatment for renal failure patients. The Allient(R) System has not been evaluated by the FDA.

This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company's control. Events which could cause results to differ include, failure to meet on-going developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement, for the companies products/services and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.